Biocytogen and Qilu Pharmaceutical Enter Non-Exclusive Licensing Agreement for Fully Human VHH Antibody in Neuroscience
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SSE: 688796; HKEX: 02315), a biotechnology company focused on the discovery and development of innovative antibody-based therapeutics, has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd., a leading pharmaceutical company in China. Under the agreement, Biocytogen will provide Qilu Pharmaceutical with non-exclusive rights to a fully human VHH antibody molecule for research and development activities aimed at advancing innovative therapeutic programs in the neuroscience field.
The collaboration highlights the growing interest in VHH antibody technologies as pharmaceutical companies explore new molecular formats capable of addressing challenging therapeutic targets and disease areas. Neuroscience remains an area of significant unmet medical need, with many neurological disorders presenting complex biological mechanisms, difficult-to-reach targets, and substantial barriers to drug development. The agreement brings together Biocytogen’s antibody discovery capabilities and Qilu Pharmaceutical’s established research, development, manufacturing, and commercialization infrastructure.
Fully Human VHH Molecule Generated Through RenNano® Platform
The VHH antibody molecule covered by the agreement was generated using Biocytogen’s proprietary RenNano® platform. The technology is designed to facilitate the discovery of fully human VHH antibody molecules with desirable molecular characteristics, including target specificity, binding affinity, and developability.
VHH antibodies represent a specialized antibody format that can provide researchers with additional flexibility when designing therapeutic molecules. Their molecular characteristics may support the development of therapies against targets and biological mechanisms that can be difficult to address using conventional antibody formats. Depending on the therapeutic strategy, VHH molecules can also serve as building blocks for more complex drug modalities.
Biocytogen’s RenNano® platform is designed to generate fully human VHH antibody molecules that can potentially be incorporated into a range of therapeutic approaches. These include standalone VHH antibodies as well as bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), and other innovative antibody-based modalities.
The platform’s ability to generate molecular building blocks could provide pharmaceutical developers with greater flexibility in selecting and optimizing therapeutic formats. This flexibility is particularly relevant to neuroscience, where the biological characteristics of disease targets can vary considerably and may require differentiated approaches to molecular design and delivery.
Through the licensing agreement, Qilu Pharmaceutical will be able to evaluate and advance the licensed VHH molecule according to its own research and development strategy. The parties have also agreed that the eventual development modality can be determined flexibly based on the characteristics of the project, scientific findings, and specific therapeutic requirements.
Supporting Innovation in Neuroscience
Neuroscience drug development continues to be one of the most scientifically demanding areas of pharmaceutical research. Neurological diseases can involve complex interactions among multiple biological pathways, making target identification, validation, and therapeutic intervention particularly challenging.
In addition to biological complexity, researchers often face difficulties related to drug distribution, tissue penetration, target accessibility, and the translation of preclinical findings into clinical outcomes. These challenges have increased interest in innovative molecular formats and discovery platforms that may offer alternative approaches to developing therapies for neurological conditions.
The collaboration between Biocytogen and Qilu Pharmaceutical reflects this broader industry effort to identify new molecular solutions for complex therapeutic areas. By combining a fully human VHH molecule generated through Biocytogen’s RenNano® platform with Qilu Pharmaceutical’s internal R&D capabilities, the companies aim to support further investigation of a potential innovative therapeutic program in neuroscience.
The agreement does not specify the particular neurological indication or target associated with the licensed molecule. Instead, Qilu Pharmaceutical will have the opportunity to determine the appropriate research and development pathway based on its strategic priorities and evaluation of the molecule.
Qilu Pharmaceutical Expands Innovative Drug Development
Qilu Pharmaceutical has developed an extensive pharmaceutical business in China and has pursued an innovation-driven development strategy across multiple therapeutic and technology areas. Its activities include chemical drugs, biologics, and innovative therapeutics, supported by capabilities covering different stages of the pharmaceutical product lifecycle.
These capabilities include early-stage research and discovery, drug development, manufacturing, and commercialization. Such an integrated infrastructure can enable pharmaceutical companies to move promising molecular assets through multiple stages of development while maintaining continuity between research, clinical development, manufacturing, and market preparation.
The licensing agreement with Biocytogen provides Qilu Pharmaceutical with access to an additional antibody technology asset that can be evaluated within its broader innovation strategy. The non-exclusive structure of the agreement also provides flexibility for Biocytogen to continue pursuing additional collaborations involving its VHH antibody assets.
For Biocytogen, the agreement represents another opportunity to apply its RenNano® platform to a new therapeutic area and expand the potential use of its fully human VHH antibody molecules. The collaboration also demonstrates how proprietary antibody discovery technologies can support external pharmaceutical development programs through licensing and strategic partnerships.
Biocytogen Highlights Potential of VHH Antibody Technology
Commenting on the collaboration, Dr. Yuelei Shen, President and CEO of Biocytogen, emphasized the scientific challenges associated with neuroscience drug development and the potential contribution of VHH antibodies to innovative therapeutic design.
According to Dr. Shen, neuroscience drug development involves significant scientific and translational barriers and requires careful consideration of target biology, molecular quality, and downstream development strategies. He noted that the distinctive characteristics of VHH antibodies could create additional opportunities for drug design in complex disease areas.
Dr. Shen also highlighted Qilu Pharmaceutical’s capabilities in innovative drug research and industrialization. He expressed the company’s expectation that the licensed fully human VHH antibody molecule could be integrated into Qilu Pharmaceutical’s R&D system and potentially contribute to the exploration of innovative neuroscience programs.
The comments underscore the strategic rationale behind the agreement: rather than focusing solely on a conventional antibody-development pathway, the collaboration allows the licensed molecule to be evaluated for different potential applications and development formats.
Flexible Development Strategy
One of the notable aspects of the agreement is the flexibility surrounding the future development modality of the licensed molecule. Rather than committing to a single predefined format, Qilu Pharmaceutical can determine the most appropriate development strategy based on project-specific characteristics and therapeutic objectives.
This approach may allow researchers to assess whether the VHH molecule is best suited for development as an individual therapeutic or as part of a more sophisticated molecular architecture. Potential approaches could include the incorporation of VHH components into bispecific or multispecific antibodies, ADCs, or other innovative modalities.
Such flexibility is increasingly important in modern drug development, where the same molecular binding component can potentially be adapted to different therapeutic strategies. Advances in antibody engineering have enabled researchers to design molecules with multiple functions, potentially improving target engagement, specificity, pharmacological activity, or other characteristics relevant to therapeutic development.
For neuroscience programs, the ability to explore different molecular configurations may be particularly valuable because successful drug development can depend on overcoming several biological and pharmacological challenges simultaneously.
Financial Terms and Future Milestones
Under the terms of the licensing agreement, Biocytogen will receive an upfront payment from Qilu Pharmaceutical. In addition, Biocytogen is eligible to receive milestone payments if specified development, regulatory, and commercial milestones are achieved for products associated with the licensed molecule.
The companies have not disclosed the amount of the upfront payment or the potential value of the milestone payments. Other financial terms of the agreement also remain undisclosed.
The milestone structure provides Biocytogen with the potential to receive additional financial benefits as the licensed program advances through development and, potentially, regulatory and commercial stages. For Qilu Pharmaceutical, the agreement provides access to an externally generated antibody asset that can be assessed alongside its existing discovery and development programs.
The actual progression of the molecule will depend on subsequent research, development activities, regulatory considerations, and the results generated during the development process.
Expanding Opportunities for Antibody-Based Therapeutics
The collaboration between Biocytogen and Qilu Pharmaceutical reflects the continuing evolution of antibody-based drug discovery. Pharmaceutical developers are increasingly exploring novel antibody formats to expand the range of targets and diseases that can potentially be addressed with biologic therapies.
VHH antibodies are one component of this broader evolution. Their potential use as standalone molecules or as components of more complex therapeutic constructs provides developers with additional options when designing next-generation biologics.
For Biocytogen, the agreement further demonstrates the potential commercial and scientific applications of its RenNano® platform. By licensing fully human VHH antibody assets to pharmaceutical partners, the company can extend the reach of its discovery technologies while enabling partners to pursue development programs aligned with their own strategic priorities.
For Qilu Pharmaceutical, access to the licensed molecule adds another potential asset to its innovative drug development activities and creates an opportunity to investigate a novel antibody format within neuroscience.
Overall, the non-exclusive licensing agreement establishes a framework for further research and development of a fully human VHH antibody molecule generated through Biocytogen’s RenNano® platform. While the specific therapeutic program and development pathway have not been disclosed, the collaboration underscores the potential role of advanced antibody technologies in addressing challenging areas of drug discovery.
As Qilu Pharmaceutical evaluates the molecule and determines its future development strategy, the partnership could contribute to broader efforts to develop innovative treatments for neurological diseases. At the same time, the agreement expands Biocytogen’s ability to collaborate with pharmaceutical companies across therapeutic areas, reinforcing the potential of its fully human VHH antibody discovery platform as a source of building blocks for next-generation biologic therapeutics.
About Biocytogen
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration.
As of June 30, 2026, more than 455 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide.